Save Meropenem/Vaborbactam for Carbapenem-Resistant Enterobacteriaceae

December 2017

Meropenem/vaborbactam (Vabomere, VAY-boh-meer) will be the first antibiotic to combine a carbapenem with a beta-lactamase inhibitor.

Adding the beta-lactamase inhibitor vaborbactam helps meropenem outsmart carbapenem-resistant superbugs, which cause about 9,000 infections in the U.S. each year.

Meropenem/vaborbactam is approved to treat complicated urinary tract infections (UTIs), including pyelonephritis. Early evidence suggests it's also effective for bacteremia, pneumonia, and intra-abdominal infections.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

New Drugs Save Meropenem/Vaborbactam for Carbapenem-Resistant Enterobacteriaceae
Dosing Don't Use Creatinine Clearance to Renally Dose All Meds
Hematology & Oncology Consider a Fixed Dose of Rasburicase for Tumor Lysis Syndrome
Cardiology Look for Post-MI Patients Who May Benefit From an Aldosterone Antagonist
New Drugs Watch for Confusion Between Fiasp and NovoLog
Gastroenterology Know How to Manage Antithrombotics Around Emergent Colonoscopies
New Drugs Emphasize an Effective Bowel Regimen for Opioid-Induced Constipation
COPD Ensure Patients With Mild COPD Are on the Most Cost-Effective Regimen
New Drugs Consider Endari for Patients on Hydroxyurea Who Still Have Sickle Cell Crises
Infectious Diseases Check if Your Hospital Uses Rapid Diagnostic Tests for Acute Infectious Diarrhea
Vaccines Help Patients Understand Differences Between Zostavax and Shingrix

Save Meropenem/Vaborbactam for Carbapenem-Resistant Enterobacteriaceae

Get unlimited access through an Enterprise license

Table of Contents